LT4052B - Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof - Google Patents

Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof Download PDF

Info

Publication number
LT4052B
LT4052B LT96-028A LT96028A LT4052B LT 4052 B LT4052 B LT 4052B LT 96028 A LT96028 A LT 96028A LT 4052 B LT4052 B LT 4052B
Authority
LT
Lithuania
Prior art keywords
compound
crystalline anhydrous
temperature
composition
salt
Prior art date
Application number
LT96-028A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT96028A (en
Inventor
Roger Cherng Fu
De-Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of LT96028A publication Critical patent/LT96028A/xx
Publication of LT4052B publication Critical patent/LT4052B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LT96-028A 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof LT4052B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15

Publications (2)

Publication Number Publication Date
LT96028A LT96028A (en) 1996-08-26
LT4052B true LT4052B (en) 1996-10-25

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
LT96-028A LT4052B (en) 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Country Status (31)

Country Link
US (2) US5543408A (de)
EP (1) EP0724581B1 (de)
JP (1) JP3411038B2 (de)
KR (1) KR100349772B1 (de)
CN (1) CN1060770C (de)
AT (1) ATE173475T1 (de)
AU (1) AU677435B2 (de)
BR (1) BR9407469A (de)
CA (1) CA2171836C (de)
CZ (1) CZ292423B6 (de)
DE (1) DE69414720T2 (de)
DK (1) DK0724581T3 (de)
ES (1) ES2123831T3 (de)
FI (1) FI119639B (de)
HU (1) HU217300B (de)
IL (1) IL110970A (de)
LT (1) LT4052B (de)
LV (1) LV11326B (de)
MX (1) MXPA94007099A (de)
NO (1) NO314727B1 (de)
NZ (1) NZ273801A (de)
PH (1) PH30685A (de)
PL (1) PL178522B1 (de)
RO (2) RO118075B1 (de)
RU (1) RU2132849C1 (de)
SG (1) SG55006A1 (de)
SI (1) SI9420052B (de)
TW (1) TW370527B (de)
UA (1) UA49797C2 (de)
WO (1) WO1995007902A1 (de)
ZA (1) ZA947088B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (de) * 1998-12-09 2002-11-30 Biocon Ltd
CZ292123B6 (cs) * 2001-06-08 2003-08-13 Ivax Pharmaceuticals S.R.O. Způsob přípravy mykofenolátu mofetilu
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
DE602004015310D1 (de) * 2003-09-11 2008-09-04 Sandoz Ag Verfahren zur herstellung von mycophenolatmofetil
WO2005105768A2 (en) * 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) * 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
TWI322147B (en) * 2004-07-20 2010-03-21 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
EP1917010A2 (de) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Zusammensetzungen und verfahren zur behandlung von gefäss-, autoimmun- und entzündlichen erkrankungen
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP2436381A1 (de) 2006-06-27 2012-04-04 Sandoz AG Kristallisierung von Halogenwasserstoffen von pharmazeutischen Verbindungen
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
CA3212370A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
SU1170760A1 (ru) * 1984-02-20 1996-09-20 Ф.Ю. Рачинский Дигидробромид 2-(2-морфолиноэтилтио)бензимидазола, повышающий физическую работоспособность и ускоряющий процессы восстановления после физических нагрузок и длительного стресса
FR2653999A1 (fr) * 1989-11-06 1991-05-10 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4786637A (en) 1987-01-30 1988-11-22 Syntex (U.S.A.) Inc. Treatment of allograft rejection with mycophenolic acid morpholinoethylester and derivatives thereof
US4808592A (en) 1987-01-30 1989-02-28 Syntex (U.S.A.) Inc. Method of treating diseases by administering morpholinoethylester of mycophenolic acid and derivatives thereof
US4948793A (en) 1987-01-30 1990-08-14 Syntex (U.S.A.) Inc. Treatment of autoimmune diseases with the morpholinoethyl ester of mycophenolic acid, and derivatives thereof
US4952579A (en) 1987-01-30 1990-08-28 Syntex (U.S.A.) Inc. Method of treating diseases by administering morpholino-ethylester of mycophenolic acid or derivatives thereof
US4992467A (en) 1987-01-30 1991-02-12 Syntex (U.S.A.) Inc. Treatment of autoimmune diseases with mycophenolic acid, and derivatives and formulations thereof

Also Published As

Publication number Publication date
RO118075B1 (ro) 2003-01-30
LT96028A (en) 1996-08-26
HUT75119A (en) 1997-04-28
WO1995007902A1 (en) 1995-03-23
ZA947088B (en) 1996-03-14
PL313480A1 (en) 1996-07-08
CZ78896A3 (en) 1996-10-16
EP0724581B1 (de) 1998-11-18
DK0724581T3 (da) 1999-08-02
NO961075D0 (no) 1996-03-15
UA49797C2 (uk) 2002-10-15
RU2132849C1 (ru) 1999-07-10
RO118427B1 (ro) 2003-05-30
PL178522B1 (pl) 2000-05-31
SI9420052B (sl) 2004-02-29
FI119639B (fi) 2009-01-30
PH30685A (en) 1997-09-16
AU677435B2 (en) 1997-04-24
JPH09502721A (ja) 1997-03-18
LV11326A (lv) 1996-06-20
ES2123831T3 (es) 1999-01-16
FI961169L (fi) 1996-03-13
FI961169A0 (fi) 1996-03-13
CZ292423B6 (cs) 2003-09-17
KR100349772B1 (ko) 2002-12-28
IL110970A (en) 1999-01-26
JP3411038B2 (ja) 2003-05-26
HK1012624A1 (en) 1999-08-06
NO961075L (no) 1996-03-15
CA2171836C (en) 2006-11-14
MXPA94007099A (es) 2004-01-23
TW370527B (en) 1999-09-21
DE69414720T2 (de) 1999-04-08
SG55006A1 (en) 1998-12-21
US5543408A (en) 1996-08-06
HU9600652D0 (en) 1996-05-28
CN1131420A (zh) 1996-09-18
HU217300B (hu) 1999-12-28
AU7723894A (en) 1995-04-03
IL110970A0 (en) 1994-11-28
DE69414720D1 (de) 1998-12-24
BR9407469A (pt) 1996-11-12
EP0724581A1 (de) 1996-08-07
SI9420052A (en) 1996-12-31
CN1060770C (zh) 2001-01-17
ATE173475T1 (de) 1998-12-15
NZ273801A (en) 1997-10-24
NO314727B1 (no) 2003-05-12
US5545637A (en) 1996-08-13
CA2171836A1 (en) 1995-03-23
LV11326B (en) 1996-10-20

Similar Documents

Publication Publication Date Title
JP3411038B2 (ja) ミコフェノール酸モフェチルの結晶質無水物およびその静注用製剤
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
JP2022185009A (ja) 安定したアザシチジン含有医薬組成物の製造方法
US5972912A (en) Method for lyophilizing ifosfamide
KR102099711B1 (ko) TGF-β1 유전자의 발현을 억제하는 단일-가닥 핵산 분자를 안정적으로 함유하는 조성물
EP2440180B1 (de) Injektions- und infusionslösungen aus ipamorelindiacetat
HK1012624B (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
KR0137647B1 (ko) 이보파민의 수용성 산 부가 염을 포함하는 안과용 약학 조성물
CA2503087A1 (en) Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
WO2025165852A1 (en) Liquid formulations of lurbinectedin
JPH0158161B2 (de)
JPS639490B2 (de)
JPS6352608B2 (de)

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20140912